Shares of CytomX Therapeutics (NASDAQ:CTMX) fell on Tuesday after the cancer drug developer announced a roughly 40% reduction in its workforce as part of a portfolio reorganization drive aimed at cost savings.
Citing plans to allocate resources to the maximum